# Submassive and Massive Pulmonary Embolism Treatment With Ultrasound Accelerated Thrombolysis Therapy

Study · id `cardio:ct-nct01513759` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01513759](<https://clinicaltrials.gov/study/NCT01513759>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT01513759

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 150 participants.

## Technical summary

Registry record NCT01513759. Allocation not applicable; no masking; primary purpose treatment. Start 2012-06-07 (actual); primary completion 2013-02-17 (actual). Results posted on 2019-07-05.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 150 participants (enrolled count; ClinicalTrials.gov record NCT01513759, source copy `cardio:ctgov-nct01513759-2021-07-19`, retrieved 2026-10-31)
- Started: 2012-06-07 (actual) (ClinicalTrials.gov record NCT01513759, source copy `cardio:ctgov-nct01513759-2021-07-19`, retrieved 2026-10-31)
- Primary completion: 2013-02-17 (actual) (ClinicalTrials.gov record NCT01513759, source copy `cardio:ctgov-nct01513759-2021-07-19`, retrieved 2026-10-31)
- Completion: 2013-02-17 (actual) (ClinicalTrials.gov record NCT01513759, source copy `cardio:ctgov-nct01513759-2021-07-19`, retrieved 2026-10-31)
- Results first posted: 2019-07-05 (ClinicalTrials.gov record NCT01513759, source copy `cardio:ctgov-nct01513759-2021-07-19`, retrieved 2026-10-31)
- Countries: United States (ClinicalTrials.gov record NCT01513759, source copy `cardio:ctgov-nct01513759-2021-07-19`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01513759-2021-07-19`, retrieved 2026-10-31)

## The registry's words

- Brief title: Submassive and Massive Pulmonary Embolism Treatment With Ultrasound Accelerated Thrombolysis Therapy
- Acronym: SEATTLE II
- Condition: Pulmonary Embolism
- Condition: Acute Pulmonary Embolism
- Condition: Sub-massive Pulmonary Embolism
- Condition: Massive Pulmonary Embolism
- Condition: Pulmonary Thromboembolism
- Intervention (Drug): recombinant tissue plasminogen activator
- Intervention (Device): EKOS EkoSonic Endovascular System
- Lead sponsor: Boston Scientific Corporation
- Lead sponsor class: INDUSTRY
- Collaborator: EKOS Corporation
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Pulmonary embolism (`cardio:pulmonary-embolism`)
- Registry lists this organization as the lead sponsor: Boston Scientific (`cardio:boston-scientific`)

## Provenance

Content hash: ed7babc8adafb14e56733238db3d581961ad44f3d64741b0632463522955becf
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
